Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist.

Eur J Immunol

Institute for Virology and Immunobiology, University of Würzburg, Versbacherstrasse 7, D-97078 Würzburg, Germany.

Published: March 2003

CD4(+)CD25(+) T cells play a central role in the suppression of autoimmunity and inflammation, making their in vivo expansion a highly attractive therapeutic target. By phenotyping with a novel rat CTL antigen-4 (CTLA-4)-specific monoclonal antibody (mAb) and functional in vitro assays, we here first establish that rat CD4(+)CD25(+) T cells correspond to the regulatory T cells (Treg cells) described in mice and humans: they constitutively express CTLA-4, produce IL-10 but not IL-2, and are able to suppress the proliferation of costimulated CD25-negative indicator cells. Furthermore, we show that rat Treg cells respond less well than CD25(-) T cells to conventional costimulation, but are readily expanded in vitro with "superagonistic" CD28-specific mAb which are potent mitogens for all T cells without the need for TCR engagement. In vivo, functional Treg cells are preferentially expanded by CD28 stimulation over other T cell subsets, leading to a 20-fold increase within 3 days in response to a single antibody dose. These data suggest that CD28-driven activation of Treg cells may be highly effective in the treatment of inflammatory and autoimmune diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.200323570DOI Listing

Publication Analysis

Top Keywords

treg cells
16
cells
11
regulatory cells
8
cd4+cd25+ cells
8
efficient expansion
4
expansion regulatory
4
cells vitro
4
vitro vivo
4
vivo cd28
4
cd28 superagonist
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!